PI3K-IN-27

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K-IN-27 

PI3K-IN-27 是一种有效的 PI3K 抑制剂。PI3K 属于脂质信号激酶大家族,在细胞生长、分化、迁移和细胞凋亡 apoptosis 等细胞过程中起关键作用。PI3K-IN-27 具有研究癌症和炎症等过度增殖性疾病或免疫和自身免疫性疾病的潜力 (信息摘自专利 WO2021233227A1,化合物 1)。

PI3K-IN-27

PI3K-IN-27 Chemical Structure

CAS No. : 2742654-38-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K-IN-27 is a potent inhibitor of PI3K. PI3K belongs to a large family of lipid signaling kinase that plays key role in cellular process including cell growth, differentiation, migration and apoptosis. PI3K-IN-27 has the potential for the research of hyper-proliferative diseases like cancer and inflammation, or immune and autoimmune diseases (extracted from patent WO2021233227A1, compound 1)[1].

分子量

572.63

Formula

C30H26F2N6O2S

CAS 号

2742654-38-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Zuwen ZHOU, et al. Compounds as protein kinase inhibitors. Patent WO2021233227A1.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI3K-IN-27

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K-IN-27 

PI3K-IN-27 是一种有效的 PI3K 抑制剂。PI3K 属于脂质信号激酶大家族,在细胞生长、分化、迁移和细胞凋亡 apoptosis 等细胞过程中起关键作用。PI3K-IN-27 具有研究癌症和炎症等过度增殖性疾病或免疫和自身免疫性疾病的潜力 (信息摘自专利 WO2021233227A1,化合物 1)。

PI3K-IN-27

PI3K-IN-27 Chemical Structure

CAS No. : 2742654-38-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K-IN-27 is a potent inhibitor of PI3K. PI3K belongs to a large family of lipid signaling kinase that plays key role in cellular process including cell growth, differentiation, migration and apoptosis. PI3K-IN-27 has the potential for the research of hyper-proliferative diseases like cancer and inflammation, or immune and autoimmune diseases (extracted from patent WO2021233227A1, compound 1)[1].

分子量

572.63

Formula

C30H26F2N6O2S

CAS 号

2742654-38-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Zuwen ZHOU, et al. Compounds as protein kinase inhibitors. Patent WO2021233227A1.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI3K-IN-27

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K-IN-27 

PI3K-IN-27 是一种有效的 PI3K 抑制剂。PI3K 属于脂质信号激酶大家族,在细胞生长、分化、迁移和细胞凋亡 apoptosis 等细胞过程中起关键作用。PI3K-IN-27 具有研究癌症和炎症等过度增殖性疾病或免疫和自身免疫性疾病的潜力 (信息摘自专利 WO2021233227A1,化合物 1)。

PI3K-IN-27

PI3K-IN-27 Chemical Structure

CAS No. : 2742654-38-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K-IN-27 is a potent inhibitor of PI3K. PI3K belongs to a large family of lipid signaling kinase that plays key role in cellular process including cell growth, differentiation, migration and apoptosis. PI3K-IN-27 has the potential for the research of hyper-proliferative diseases like cancer and inflammation, or immune and autoimmune diseases (extracted from patent WO2021233227A1, compound 1)[1].

分子量

572.63

Formula

C30H26F2N6O2S

CAS 号

2742654-38-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Zuwen ZHOU, et al. Compounds as protein kinase inhibitors. Patent WO2021233227A1.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI3K-IN-26

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K-IN-26 

PI3K-IN-26 是一种有效的 PI3K 抑制剂,对 SU-DHL-6 细胞的 IC50 为 36 nM (WO2016066142A1, compound 1)。

PI3K-IN-26

PI3K-IN-26 Chemical Structure

CAS No. : 1918151-65-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K-IN-26 is a potent PI3K inhibitor with an IC50 of 36 nM for SU-DHL-6 cells (WO2016066142A1, compound 1)[1].

分子量

402.47

Formula

C21H18N6OS

CAS 号

1918151-65-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Certain protein kinase inhibitors. WO2016066142A1.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI3K-IN-26

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K-IN-26 

PI3K-IN-26 是一种有效的 PI3K 抑制剂,对 SU-DHL-6 细胞的 IC50 为 36 nM (WO2016066142A1, compound 1)。

PI3K-IN-26

PI3K-IN-26 Chemical Structure

CAS No. : 1918151-65-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K-IN-26 is a potent PI3K inhibitor with an IC50 of 36 nM for SU-DHL-6 cells (WO2016066142A1, compound 1)[1].

分子量

402.47

Formula

C21H18N6OS

CAS 号

1918151-65-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Certain protein kinase inhibitors. WO2016066142A1.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI3K-IN-26

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K-IN-26 

PI3K-IN-26 是一种有效的 PI3K 抑制剂,对 SU-DHL-6 细胞的 IC50 为 36 nM (WO2016066142A1, compound 1)。

PI3K-IN-26

PI3K-IN-26 Chemical Structure

CAS No. : 1918151-65-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K-IN-26 is a potent PI3K inhibitor with an IC50 of 36 nM for SU-DHL-6 cells (WO2016066142A1, compound 1)[1].

分子量

402.47

Formula

C21H18N6OS

CAS 号

1918151-65-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Certain protein kinase inhibitors. WO2016066142A1.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI3K-IN-30

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K-IN-30 

PI3K-IN-30 (compound 6d) 是一种有效的 PI3K 抑制剂,对于 PI3Kα、PI3Kβ、PI3Kγ 和 PI3Kδ,IC50 分别为 5.1 nM、136 nM、30.7 nM 和 8.9 nM。

PI3K-IN-30

PI3K-IN-30 Chemical Structure

CAS No. : 2281803-22-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K-IN-30 (compound 6d) is a potent PI3K inhibitor with IC50s of 5.1, 136, 30.7 and 8.9 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively[1].

IC50 & Target[1]

PI3Kα

5.1 nM (IC50)

PI3Kβ

136 nM (IC50)

PI3Kγ

30.7 nM (IC50)

PI3Kδ

8.9 nM (IC50)

分子量

449.45

Formula

C20H25F2N7O3

CAS 号

2281803-22-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Van Dort ME, et al. Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors. Eur J Med Chem. 2022;229:113996.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI3K-IN-30

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K-IN-30 

PI3K-IN-30 (compound 6d) 是一种有效的 PI3K 抑制剂,对于 PI3Kα、PI3Kβ、PI3Kγ 和 PI3Kδ,IC50 分别为 5.1 nM、136 nM、30.7 nM 和 8.9 nM。

PI3K-IN-30

PI3K-IN-30 Chemical Structure

CAS No. : 2281803-22-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K-IN-30 (compound 6d) is a potent PI3K inhibitor with IC50s of 5.1, 136, 30.7 and 8.9 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively[1].

IC50 & Target[1]

PI3Kα

5.1 nM (IC50)

PI3Kβ

136 nM (IC50)

PI3Kγ

30.7 nM (IC50)

PI3Kδ

8.9 nM (IC50)

分子量

449.45

Formula

C20H25F2N7O3

CAS 号

2281803-22-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Van Dort ME, et al. Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors. Eur J Med Chem. 2022;229:113996.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI3K-IN-29

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K-IN-29 

PI3K-IN-29 是一种有效的 PI3K 抑制剂。PI3K-IN-29 对 U87MG、HeLa 和 HL60 细胞具有较好的抑制作用,IC50 值分别为 0.264、2.04 和 1.14 µM。PI3K-IN-29 通过抑制 PI3K 催化的 Akt 的磷酸化来抑制 PI3K/Akt 通路。

PI3K-IN-29

PI3K-IN-29 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K-IN-29 is a potent PI3K inhibitor. PI3K-IN-29 displays good inhibition potencies against U87MG, HeLa and HL60 cells with IC50 values of 0.264, 2.04 and 1.14 µM, respectively. PI3K-IN-29 inhibits PI3K/Akt pathway by inhibiting phosphorylation of Akt that is catalyzed by PI3K[1].

体外研究
(In Vitro)

PI3K-IN-29 (compound 25) (72 h) displays good inhibition potencies against U87MG, HeLa and HL60 cells with IC50 values of 0.264, 2.04 and 1.14 µM, respectively[1].
PI3K-IN-29 (U87MG cells; 1, 5 µM; 1 h) inhibits PI3K/Akt pathway by inhibiting phosphorylation of Akt that is catalyzed by PI3K[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: U87MG, HeLa, HepG2, A549, HL60, MCF7 cells
Concentration:
Incubation Time: 72 h
Result: Displayed good inhibition potencies against U87MG, HeLa and HL60 cells with IC50 values of 0.264, 2.04 and 1.14 µM, respectively.

Western Blot Analysis[1]

Cell Line: U87MG cells
Concentration: 1, 5 µM
Incubation Time: 1 h
Result: Inhibited PI3K/Akt pathway by inhibiting phosphorylation of Akt that was catalyzed by PI3K.

分子量

560.03

Formula

C27H22ClN7O3S

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Tian C, et al. Discovery of cinnoline derivatives as potent PI3K inhibitors with antiproliferative activity. Bioorg Med Chem Lett. 2021, 48:128271.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI3K-IN-30

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K-IN-30 

PI3K-IN-30 (compound 6d) 是一种有效的 PI3K 抑制剂,对于 PI3Kα、PI3Kβ、PI3Kγ 和 PI3Kδ,IC50 分别为 5.1 nM、136 nM、30.7 nM 和 8.9 nM。

PI3K-IN-30

PI3K-IN-30 Chemical Structure

CAS No. : 2281803-22-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K-IN-30 (compound 6d) is a potent PI3K inhibitor with IC50s of 5.1, 136, 30.7 and 8.9 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively[1].

IC50 & Target[1]

PI3Kα

5.1 nM (IC50)

PI3Kβ

136 nM (IC50)

PI3Kγ

30.7 nM (IC50)

PI3Kδ

8.9 nM (IC50)

分子量

449.45

Formula

C20H25F2N7O3

CAS 号

2281803-22-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Van Dort ME, et al. Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors. Eur J Med Chem. 2022;229:113996.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI3K-IN-29

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K-IN-29 

PI3K-IN-29 是一种有效的 PI3K 抑制剂。PI3K-IN-29 对 U87MG、HeLa 和 HL60 细胞具有较好的抑制作用,IC50 值分别为 0.264、2.04 和 1.14 µM。PI3K-IN-29 通过抑制 PI3K 催化的 Akt 的磷酸化来抑制 PI3K/Akt 通路。

PI3K-IN-29

PI3K-IN-29 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K-IN-29 is a potent PI3K inhibitor. PI3K-IN-29 displays good inhibition potencies against U87MG, HeLa and HL60 cells with IC50 values of 0.264, 2.04 and 1.14 µM, respectively. PI3K-IN-29 inhibits PI3K/Akt pathway by inhibiting phosphorylation of Akt that is catalyzed by PI3K[1].

体外研究
(In Vitro)

PI3K-IN-29 (compound 25) (72 h) displays good inhibition potencies against U87MG, HeLa and HL60 cells with IC50 values of 0.264, 2.04 and 1.14 µM, respectively[1].
PI3K-IN-29 (U87MG cells; 1, 5 µM; 1 h) inhibits PI3K/Akt pathway by inhibiting phosphorylation of Akt that is catalyzed by PI3K[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: U87MG, HeLa, HepG2, A549, HL60, MCF7 cells
Concentration:
Incubation Time: 72 h
Result: Displayed good inhibition potencies against U87MG, HeLa and HL60 cells with IC50 values of 0.264, 2.04 and 1.14 µM, respectively.

Western Blot Analysis[1]

Cell Line: U87MG cells
Concentration: 1, 5 µM
Incubation Time: 1 h
Result: Inhibited PI3K/Akt pathway by inhibiting phosphorylation of Akt that was catalyzed by PI3K.

分子量

560.03

Formula

C27H22ClN7O3S

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Tian C, et al. Discovery of cinnoline derivatives as potent PI3K inhibitors with antiproliferative activity. Bioorg Med Chem Lett. 2021, 48:128271.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI3K-IN-29

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K-IN-29 

PI3K-IN-29 是一种有效的 PI3K 抑制剂。PI3K-IN-29 对 U87MG、HeLa 和 HL60 细胞具有较好的抑制作用,IC50 值分别为 0.264、2.04 和 1.14 µM。PI3K-IN-29 通过抑制 PI3K 催化的 Akt 的磷酸化来抑制 PI3K/Akt 通路。

PI3K-IN-29

PI3K-IN-29 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K-IN-29 is a potent PI3K inhibitor. PI3K-IN-29 displays good inhibition potencies against U87MG, HeLa and HL60 cells with IC50 values of 0.264, 2.04 and 1.14 µM, respectively. PI3K-IN-29 inhibits PI3K/Akt pathway by inhibiting phosphorylation of Akt that is catalyzed by PI3K[1].

体外研究
(In Vitro)

PI3K-IN-29 (compound 25) (72 h) displays good inhibition potencies against U87MG, HeLa and HL60 cells with IC50 values of 0.264, 2.04 and 1.14 µM, respectively[1].
PI3K-IN-29 (U87MG cells; 1, 5 µM; 1 h) inhibits PI3K/Akt pathway by inhibiting phosphorylation of Akt that is catalyzed by PI3K[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: U87MG, HeLa, HepG2, A549, HL60, MCF7 cells
Concentration:
Incubation Time: 72 h
Result: Displayed good inhibition potencies against U87MG, HeLa and HL60 cells with IC50 values of 0.264, 2.04 and 1.14 µM, respectively.

Western Blot Analysis[1]

Cell Line: U87MG cells
Concentration: 1, 5 µM
Incubation Time: 1 h
Result: Inhibited PI3K/Akt pathway by inhibiting phosphorylation of Akt that was catalyzed by PI3K.

分子量

560.03

Formula

C27H22ClN7O3S

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Tian C, et al. Discovery of cinnoline derivatives as potent PI3K inhibitors with antiproliferative activity. Bioorg Med Chem Lett. 2021, 48:128271.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI3K/AKT-IN-1

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K/AKT-IN-1 

PI3K/AKT-IN-1 是一种有效的 PI3K/AKT 双重抑制剂 (PI3Kγ、PI3Kδ 和 AKT 的 IC50分别为 6.99 μM、4.01 μM 和 3.36 μM)。PI3K/AKT-IN-1 具有抗癌活性,其作用机制是抑制 PI3K/AKT 通路,诱导 caspase 3 依赖性凋亡 (apoptosis)。

PI3K/AKT-IN-1

PI3K/AKT-IN-1 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K/AKT-IN-1 is an effective PI3K/AKT dual inhibitor (IC50 of 6.99, 4.01 and 3.36 μM for PI3Kγ, PI3Kδ and AKT, respectively). PI3K/AKT-IN-1 has anticancer activity and acts by inhibiting PI3K/AKT axis and inducing caspase 3 dependent apoptosis[1].

IC50 & Target[1]

PI3Kγ

6.99 μM (IC50)

PI3Kδ

4.01 μM (IC50)

Akt

3.36 μM (IC50)

体外研究
(In Vitro)

PI3K/AKT-IN-1 (compound 7f) (0.04-100 µM; 48 hours) has high cytotoxic activity on both cell lines with better activity on leukaemia cell line (K562 IC50=2.62 µM) than on the breast cancer cell line (MCF-7 IC50=3.22 µM)[1].
PI3K/AKT-IN-1 (2.62 µM) can promote S-phase cell cycle arrest and apoptosis induction in K562 cells[1].
PI3K/AKT-IN-1 (2.62 µM; 48 hours) causes an increase in the percentage of Annexin-V positive apoptotic cells both in the early and late stage[1].
PI3K/AKT-IN-1 (2.62 µM; 48 hours) markedly reduces the expression of PI3K, AKT, Cyclin D1 and NF-κB[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line: MCF-7 and K562 cells[1]
Concentration: 0.04-100 µM
Incubation Time: 48 hours
Result: Demonstrated high cytotoxic activity on both cell lines with better activity on leukaemia cell line (K562 IC50=2.62 µM) than on the breast cancer cell line (MCF-7 IC50=3.22 µM).

Cell Cycle Analysis

Cell Line: K562 cells[1]
Concentration: 2.62 µM
Incubation Time:
Result: Promoted S-phase cell cycle arrest and apoptosis induction.

Apoptosis Analysis

Cell Line: K562 cells[1]
Concentration: 2.62 µM
Incubation Time: 48 hours
Result: Caused an increase in the percentage of Annexin-V positive apoptotic cells both in the early and late stage.

Western Blot Analysis

Cell Line: K562 cells[1]
Concentration: 2.62 µM
Incubation Time: 48 hours
Result: Markedly reduced the expression of PI3K, p-PI3K, AKT, p-AKT, Cyclin D1 and NF-κB.

体内研究
(In Vivo)

PI3K/AKT-IN-1 (2000 mg/kg; p.o.; single) is non-toxic and is well tolerated by experimental animals[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female rats (180-200g)[1]
Dosage: 2000 mg/kg
Administration: p.o.; single
Result: The median lethal dose (LD50) was greater than the test dose (2000 mg/kg).

分子量

467.54

Formula

C23H25N5O4S

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. El-Dydamony NM, et al. Pyrimidine-5-carbonitrile based potential anticancer agents as apoptosis inducers through PI3K/AKT axis inhibition in leukaemia K562. J Enzyme Inhib Med Chem. 2022;37(1):895-911.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI3K/AKT-IN-1

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K/AKT-IN-1 

PI3K/AKT-IN-1 是一种有效的 PI3K/AKT 双重抑制剂 (PI3Kγ、PI3Kδ 和 AKT 的 IC50分别为 6.99 μM、4.01 μM 和 3.36 μM)。PI3K/AKT-IN-1 具有抗癌活性,其作用机制是抑制 PI3K/AKT 通路,诱导 caspase 3 依赖性凋亡 (apoptosis)。

PI3K/AKT-IN-1

PI3K/AKT-IN-1 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K/AKT-IN-1 is an effective PI3K/AKT dual inhibitor (IC50 of 6.99, 4.01 and 3.36 μM for PI3Kγ, PI3Kδ and AKT, respectively). PI3K/AKT-IN-1 has anticancer activity and acts by inhibiting PI3K/AKT axis and inducing caspase 3 dependent apoptosis[1].

IC50 & Target[1]

PI3Kγ

6.99 μM (IC50)

PI3Kδ

4.01 μM (IC50)

Akt

3.36 μM (IC50)

体外研究
(In Vitro)

PI3K/AKT-IN-1 (compound 7f) (0.04-100 µM; 48 hours) has high cytotoxic activity on both cell lines with better activity on leukaemia cell line (K562 IC50=2.62 µM) than on the breast cancer cell line (MCF-7 IC50=3.22 µM)[1].
PI3K/AKT-IN-1 (2.62 µM) can promote S-phase cell cycle arrest and apoptosis induction in K562 cells[1].
PI3K/AKT-IN-1 (2.62 µM; 48 hours) causes an increase in the percentage of Annexin-V positive apoptotic cells both in the early and late stage[1].
PI3K/AKT-IN-1 (2.62 µM; 48 hours) markedly reduces the expression of PI3K, AKT, Cyclin D1 and NF-κB[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line: MCF-7 and K562 cells[1]
Concentration: 0.04-100 µM
Incubation Time: 48 hours
Result: Demonstrated high cytotoxic activity on both cell lines with better activity on leukaemia cell line (K562 IC50=2.62 µM) than on the breast cancer cell line (MCF-7 IC50=3.22 µM).

Cell Cycle Analysis

Cell Line: K562 cells[1]
Concentration: 2.62 µM
Incubation Time:
Result: Promoted S-phase cell cycle arrest and apoptosis induction.

Apoptosis Analysis

Cell Line: K562 cells[1]
Concentration: 2.62 µM
Incubation Time: 48 hours
Result: Caused an increase in the percentage of Annexin-V positive apoptotic cells both in the early and late stage.

Western Blot Analysis

Cell Line: K562 cells[1]
Concentration: 2.62 µM
Incubation Time: 48 hours
Result: Markedly reduced the expression of PI3K, p-PI3K, AKT, p-AKT, Cyclin D1 and NF-κB.

体内研究
(In Vivo)

PI3K/AKT-IN-1 (2000 mg/kg; p.o.; single) is non-toxic and is well tolerated by experimental animals[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female rats (180-200g)[1]
Dosage: 2000 mg/kg
Administration: p.o.; single
Result: The median lethal dose (LD50) was greater than the test dose (2000 mg/kg).

分子量

467.54

Formula

C23H25N5O4S

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. El-Dydamony NM, et al. Pyrimidine-5-carbonitrile based potential anticancer agents as apoptosis inducers through PI3K/AKT axis inhibition in leukaemia K562. J Enzyme Inhib Med Chem. 2022;37(1):895-911.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI3K/AKT-IN-1

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K/AKT-IN-1 

PI3K/AKT-IN-1 是一种有效的 PI3K/AKT 双重抑制剂 (PI3Kγ、PI3Kδ 和 AKT 的 IC50分别为 6.99 μM、4.01 μM 和 3.36 μM)。PI3K/AKT-IN-1 具有抗癌活性,其作用机制是抑制 PI3K/AKT 通路,诱导 caspase 3 依赖性凋亡 (apoptosis)。

PI3K/AKT-IN-1

PI3K/AKT-IN-1 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K/AKT-IN-1 is an effective PI3K/AKT dual inhibitor (IC50 of 6.99, 4.01 and 3.36 μM for PI3Kγ, PI3Kδ and AKT, respectively). PI3K/AKT-IN-1 has anticancer activity and acts by inhibiting PI3K/AKT axis and inducing caspase 3 dependent apoptosis[1].

IC50 & Target[1]

PI3Kγ

6.99 μM (IC50)

PI3Kδ

4.01 μM (IC50)

Akt

3.36 μM (IC50)

体外研究
(In Vitro)

PI3K/AKT-IN-1 (compound 7f) (0.04-100 µM; 48 hours) has high cytotoxic activity on both cell lines with better activity on leukaemia cell line (K562 IC50=2.62 µM) than on the breast cancer cell line (MCF-7 IC50=3.22 µM)[1].
PI3K/AKT-IN-1 (2.62 µM) can promote S-phase cell cycle arrest and apoptosis induction in K562 cells[1].
PI3K/AKT-IN-1 (2.62 µM; 48 hours) causes an increase in the percentage of Annexin-V positive apoptotic cells both in the early and late stage[1].
PI3K/AKT-IN-1 (2.62 µM; 48 hours) markedly reduces the expression of PI3K, AKT, Cyclin D1 and NF-κB[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line: MCF-7 and K562 cells[1]
Concentration: 0.04-100 µM
Incubation Time: 48 hours
Result: Demonstrated high cytotoxic activity on both cell lines with better activity on leukaemia cell line (K562 IC50=2.62 µM) than on the breast cancer cell line (MCF-7 IC50=3.22 µM).

Cell Cycle Analysis

Cell Line: K562 cells[1]
Concentration: 2.62 µM
Incubation Time:
Result: Promoted S-phase cell cycle arrest and apoptosis induction.

Apoptosis Analysis

Cell Line: K562 cells[1]
Concentration: 2.62 µM
Incubation Time: 48 hours
Result: Caused an increase in the percentage of Annexin-V positive apoptotic cells both in the early and late stage.

Western Blot Analysis

Cell Line: K562 cells[1]
Concentration: 2.62 µM
Incubation Time: 48 hours
Result: Markedly reduced the expression of PI3K, p-PI3K, AKT, p-AKT, Cyclin D1 and NF-κB.

体内研究
(In Vivo)

PI3K/AKT-IN-1 (2000 mg/kg; p.o.; single) is non-toxic and is well tolerated by experimental animals[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female rats (180-200g)[1]
Dosage: 2000 mg/kg
Administration: p.o.; single
Result: The median lethal dose (LD50) was greater than the test dose (2000 mg/kg).

分子量

467.54

Formula

C23H25N5O4S

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. El-Dydamony NM, et al. Pyrimidine-5-carbonitrile based potential anticancer agents as apoptosis inducers through PI3K/AKT axis inhibition in leukaemia K562. J Enzyme Inhib Med Chem. 2022;37(1):895-911.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI3K/Akt/mTOR-IN-2

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K/Akt/mTOR-IN-2 

PI3K/Akt/mTOR-IN-2 是一种有效的 PI3K/AKT/mTOR 抑制剂。PI3K/Akt/mTOR-IN-2 具有抗癌作用,并对 MDA-MB-231 细胞具有选择性,IC50 为 2.29 μM。PI3K/Akt/mTOR-IN-2 可诱导癌细胞周期阻滞和细胞凋亡 (apoptosis)。

PI3K/Akt/mTOR-IN-2

PI3K/Akt/mTOR-IN-2 Chemical Structure

CAS No. : 2757804-89-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K/Akt/mTOR-IN-2 is a PI3K/AKT/mTOR pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with IC50 value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and apoptosis[1].

IC50 & Target

IC50: 2.29 μM (PI3K/AKT/mTOR) in MDA-MB-231[1]

体外研究
(In Vitro)

PI3K/Akt/mTOR-IN-2 (compound 23) (0.5 – 100 μM; 72 hours) exhibits effective anti-cancer activity with IC50s of 2.29 – 24.63 μM, of which, IC50 in MDA-MB-231 is 2.29 μM[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24, 48 and 72 hours) induces apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 48 hours) increases the expression of Bax, and decreases the expression of Bcl-2 in MDA-MB-231 cells[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces mitochondria-dependent apoptosis in MDA-MB-231 cells through disruption of MMP, accumulation of ROS, depletion of GSH and elevation of intracellular Ca2+[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line: PC3, BGC-823, A549, MCF-7, MDA-MB-231 cells and MCF-10A cells[1]
Concentration: 0.5 – 100 μM
Incubation Time: 72 hours
Result: Exhibited effective anti-cancer activity with IC50s of 2.29 – 24.63 μM, of which, IC50 in MDA-MB-231 was 2.29 μM.

Cell Cycle Analysis

Cell Line: MDA-MB-231[1]
Concentration: 1 μM, 2 μM and 4 μM
Incubation Time: 24 hours
Result: Induced growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1.

Apoptosis Analysis

Cell Line: MDA-MB-231[1]
Concentration: 1 μM, 2 μM and 4 μM
Incubation Time: 24, 48 and 72 hours
Result: Induced apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners.

Western Blot Analysis

Cell Line: MDA-MB-231[1]
Concentration: 1 μM, 2 μM and 4 μM
Incubation Time: 48 hours
Result: Increased the expression of Bax, and decreased the expression of Bcl-2

分子量

285.29

Formula

C17H13F2NO

CAS 号

2757804-89-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Qin J, Sun X, Ma Y, et al. Design, synthesis and biological evaluation of novel 1,3,4,9-tetrahydropyrano[3,4-b]indoles as potential treatment of triple negative breast cancer by suppressing PI3K/AKT/mTOR pathway [published online ahead of print, 2021 Dec 31]. Bioorg Med Chem. 2021;55:116594.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI3K/Akt/mTOR-IN-2

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K/Akt/mTOR-IN-2 

PI3K/Akt/mTOR-IN-2 是一种有效的 PI3K/AKT/mTOR 抑制剂。PI3K/Akt/mTOR-IN-2 具有抗癌作用,并对 MDA-MB-231 细胞具有选择性,IC50 为 2.29 μM。PI3K/Akt/mTOR-IN-2 可诱导癌细胞周期阻滞和细胞凋亡 (apoptosis)。

PI3K/Akt/mTOR-IN-2

PI3K/Akt/mTOR-IN-2 Chemical Structure

CAS No. : 2757804-89-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K/Akt/mTOR-IN-2 is a PI3K/AKT/mTOR pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with IC50 value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and apoptosis[1].

IC50 & Target

IC50: 2.29 μM (PI3K/AKT/mTOR) in MDA-MB-231[1]

体外研究
(In Vitro)

PI3K/Akt/mTOR-IN-2 (compound 23) (0.5 – 100 μM; 72 hours) exhibits effective anti-cancer activity with IC50s of 2.29 – 24.63 μM, of which, IC50 in MDA-MB-231 is 2.29 μM[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24, 48 and 72 hours) induces apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 48 hours) increases the expression of Bax, and decreases the expression of Bcl-2 in MDA-MB-231 cells[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces mitochondria-dependent apoptosis in MDA-MB-231 cells through disruption of MMP, accumulation of ROS, depletion of GSH and elevation of intracellular Ca2+[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line: PC3, BGC-823, A549, MCF-7, MDA-MB-231 cells and MCF-10A cells[1]
Concentration: 0.5 – 100 μM
Incubation Time: 72 hours
Result: Exhibited effective anti-cancer activity with IC50s of 2.29 – 24.63 μM, of which, IC50 in MDA-MB-231 was 2.29 μM.

Cell Cycle Analysis

Cell Line: MDA-MB-231[1]
Concentration: 1 μM, 2 μM and 4 μM
Incubation Time: 24 hours
Result: Induced growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1.

Apoptosis Analysis

Cell Line: MDA-MB-231[1]
Concentration: 1 μM, 2 μM and 4 μM
Incubation Time: 24, 48 and 72 hours
Result: Induced apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners.

Western Blot Analysis

Cell Line: MDA-MB-231[1]
Concentration: 1 μM, 2 μM and 4 μM
Incubation Time: 48 hours
Result: Increased the expression of Bax, and decreased the expression of Bcl-2

分子量

285.29

Formula

C17H13F2NO

CAS 号

2757804-89-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Qin J, Sun X, Ma Y, et al. Design, synthesis and biological evaluation of novel 1,3,4,9-tetrahydropyrano[3,4-b]indoles as potential treatment of triple negative breast cancer by suppressing PI3K/AKT/mTOR pathway [published online ahead of print, 2021 Dec 31]. Bioorg Med Chem. 2021;55:116594.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI3K-IN-31

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K-IN-31 

PI3K-IN-31 (Compound 6b) 是一种有效的 PI3K 抑制剂,对 PI3KαPI3KβPI3KγPI3KδIC50 分别为 3.7 nM、74 nM、14.6 nM 和 9.9 nM。PI3K-IN-31 具有抗癌作用。

PI3K-IN-31

PI3K-IN-31 Chemical Structure

CAS No. : 1359956-12-9

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K-IN-31 (Compound 6b) is a potent PI3K inhibitor with IC50s of 3.7 nM, 74 nM, 14.6 nM, and 9.9 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, respectively. PI3K-IN-31 has anticancer effects[1].

IC50 & Target[1]

PI3Kα

3.7 nM (IC50)

PI3Kδ

9.9 nM (IC50)

PI3Kγ

14.6 nM (IC50)

PI3Kβ

74 nM (IC50)

分子量

435.43

Formula

C19H23F2N7O3

CAS 号

1359956-12-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Marcian E Van Dort, et al. Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors. Eur J Med Chem. 2022 Feb 5;229:113996.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI3K/Akt/mTOR-IN-2

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K/Akt/mTOR-IN-2 

PI3K/Akt/mTOR-IN-2 是一种有效的 PI3K/AKT/mTOR 抑制剂。PI3K/Akt/mTOR-IN-2 具有抗癌作用,并对 MDA-MB-231 细胞具有选择性,IC50 为 2.29 μM。PI3K/Akt/mTOR-IN-2 可诱导癌细胞周期阻滞和细胞凋亡 (apoptosis)。

PI3K/Akt/mTOR-IN-2

PI3K/Akt/mTOR-IN-2 Chemical Structure

CAS No. : 2757804-89-8

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K/Akt/mTOR-IN-2 is a PI3K/AKT/mTOR pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with IC50 value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and apoptosis[1].

IC50 & Target

IC50: 2.29 μM (PI3K/AKT/mTOR) in MDA-MB-231[1]

体外研究
(In Vitro)

PI3K/Akt/mTOR-IN-2 (compound 23) (0.5 – 100 μM; 72 hours) exhibits effective anti-cancer activity with IC50s of 2.29 – 24.63 μM, of which, IC50 in MDA-MB-231 is 2.29 μM[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24, 48 and 72 hours) induces apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 48 hours) increases the expression of Bax, and decreases the expression of Bcl-2 in MDA-MB-231 cells[1].
PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces mitochondria-dependent apoptosis in MDA-MB-231 cells through disruption of MMP, accumulation of ROS, depletion of GSH and elevation of intracellular Ca2+[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line: PC3, BGC-823, A549, MCF-7, MDA-MB-231 cells and MCF-10A cells[1]
Concentration: 0.5 – 100 μM
Incubation Time: 72 hours
Result: Exhibited effective anti-cancer activity with IC50s of 2.29 – 24.63 μM, of which, IC50 in MDA-MB-231 was 2.29 μM.

Cell Cycle Analysis

Cell Line: MDA-MB-231[1]
Concentration: 1 μM, 2 μM and 4 μM
Incubation Time: 24 hours
Result: Induced growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1.

Apoptosis Analysis

Cell Line: MDA-MB-231[1]
Concentration: 1 μM, 2 μM and 4 μM
Incubation Time: 24, 48 and 72 hours
Result: Induced apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners.

Western Blot Analysis

Cell Line: MDA-MB-231[1]
Concentration: 1 μM, 2 μM and 4 μM
Incubation Time: 48 hours
Result: Increased the expression of Bax, and decreased the expression of Bcl-2

分子量

285.29

Formula

C17H13F2NO

CAS 号

2757804-89-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Qin J, Sun X, Ma Y, et al. Design, synthesis and biological evaluation of novel 1,3,4,9-tetrahydropyrano[3,4-b]indoles as potential treatment of triple negative breast cancer by suppressing PI3K/AKT/mTOR pathway [published online ahead of print, 2021 Dec 31]. Bioorg Med Chem. 2021;55:116594.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PI3K-IN-31

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

PI3K-IN-31 

PI3K-IN-31 (Compound 6b) 是一种有效的 PI3K 抑制剂,对 PI3KαPI3KβPI3KγPI3KδIC50 分别为 3.7 nM、74 nM、14.6 nM 和 9.9 nM。PI3K-IN-31 具有抗癌作用。

PI3K-IN-31

PI3K-IN-31 Chemical Structure

CAS No. : 1359956-12-9

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PI3K-IN-31 (Compound 6b) is a potent PI3K inhibitor with IC50s of 3.7 nM, 74 nM, 14.6 nM, and 9.9 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, respectively. PI3K-IN-31 has anticancer effects[1].

IC50 & Target[1]

PI3Kα

3.7 nM (IC50)

PI3Kδ

9.9 nM (IC50)

PI3Kγ

14.6 nM (IC50)

PI3Kβ

74 nM (IC50)

分子量

435.43

Formula

C19H23F2N7O3

CAS 号

1359956-12-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Marcian E Van Dort, et al. Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors. Eur J Med Chem. 2022 Feb 5;229:113996.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务